

MEDICAL PRESCRIPTION FORM

CONSULTATION CERTIFICATE / CERTIFICAT OF INFORMATION AND CONSENT FOR TESTING



Laboratoire Cerba Customer relation service Tel.: +33 (0)1 34 40 97 76

Fax: +33 (0)1 34 40 21 29 Email: intgb@lab-cerba.com

REQUEST FOR HLA TYPING

TESTING LABORATORY		Sampling		
Customer n°: LLLLL C / LL		Sampling date		
Obligatory stamp		EDTA tube of whole blood (>5mL) Shipped refrigerated within 5 days maximum		
		(room temperature tolerated)		
PATIENT		Prescriber		
SURNAME		SURNAME		
FIRST NAME		FIRST NAME		
Address		CP City		
CP City		Tél.		
Date of birth:		Fax		
		E-mail address:		
CONTEXT OF THE REQUEST		Prescribed test		
☐ Spondyloarthritis (and associated extra-articular manifestations) B27(HLA class I: B*27)		 ☐ HLA-B27 screening by flow cytometry (OPL code: 90401) or genotyping if inconclusive test or if pre-analytical time >5 days ☐ HLA Class I Locus B genotyping (B*27 allele only) (OPL code: GB27) 		
☐ Behçet's disease (and associated manifestations of aphthosis, uveitis) B51(5) (HLA class I: B*51)		☐ HLA Class I Locus B genotyping (OPL code: BHLA1)		
☐ Birdshot chorioretinopathy (and uveitis) A29 (HLA class I: A*29)		☐ HLA Class I Locus A genotyping (OPL code: AHLA1)		
☐ Rheumatoid arthritis (chronic inflammatory rheumatism) DR1, DR4, DR10 and DR14 (HLA class II: DRB1*01,*04,*10 and *14)		☐ HLA Class II Locus DRB1 genotyping (OPL code: HLADR)		
□ Narcolepsy (hypersomnia and attention disorders) DQ6 (HLA class II: DQB1*06:02)		☐ HLA Class II Locus DQB1 genotyping (OPL code: HLADQ)		
☐ Celiac disease (and gluten intolerance) DQ2 (HLA class II: DQA1*05:01/DQB1*02:01 and DQA1*05:05/DQB1*02:02) and DQ8 (HLA class II: DQA1*03/DQB1*03:02)		☐ HLA Class II Locus DQB1 and Locus DQA1 genotyping (OPL code: HLDQA)		
☐ Other (specify):		☐ Other (specify):		
Pharmacogenetics Pharmacogenetics				
☐ Screening before abacavir-based treatment (HLA B57)		HLA-B*57:01 genotyping (OPL code: B5701)		
☐ Screening before treatment with carbamazepine (HLA B15)		☐ HLA-B*15:02 and HLA-A*31:01 genotyping (OPL code: B1502) ☐ HLA-B*58:01 genotyping (OPL code: B5801)		
☐ Hypersensitivity to allopurinol (HLA B58) ☐ HLA-B*58:01 genotyping (OPL code: B5801)				
CONSULTATION CERTIFICATE FROM THE PRESCRIBING PHYSICIAN OR THE GENETIC COUNSELOR				
I certify that I have informed the undersigned patient and his/her parents (legal representatives) about the characteristics of the investigated disease, how to diagnose it, how to prevent and treat it, how the disease is transmitted and the possible consequences in other members of the family, the storage of the sample, and that I have obtained the consent of the patient AND his/her guardianship under the conditions provided for by the French public health code (articles R113-4 and 5). The patient was informed in particular: 1. The right to request at any time that this study be stopped, that the results not be communicated to me, or that the stored samples be destroyed, 2. That the result of this examination will be reported and explained by the prescribing physician (or by delegation to the genetic counsellor) according to the current state of knowledge. The patient authorizes:				
The storage of a biosample taken to me and its subsequent use to continue investigations as part of the same diagnostic process, depending			ss, depending	☐ Yes ☐ No
on the evolution of knowledge. The transmission of a sample along with the	photographs to another laboratory to complete this			
genetic study.		-	☐ Yes ☐ No	
The recording and storage of medical data use The Anonymised use of medical data and/or u		rect henefit or	☐ Yes ☐ No	
its use for internal laboratory quality assurance		TOOL DONGIN OF	☐ Yes ☐ No	
Done in		AL DEDDECENTATIVE		Descriped
PATIENT IDENTITY Last name:	Last name:	GAL REPRESENTATIVE	Last name:	PRESCRIBER
First name: Date of birth:	First name: Date of birth:		First name:	
	Relationship to the patient :			
SIGNATURE	SIGNATURE		SIGNATURE	